Menu Search
Equities

Orion Oyj

ORNBV:HEX

Orion Oyj

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)45.11
  • Today's Change0.35 / 0.78%
  • Shares traded131.70k
  • 1 Year change+22.02%
  • Beta0.5053
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform4
Hold1
Sell1
Strong Sell0

Share price forecast in EUR

The 7 analysts offering 12 month price targets for Orion Oyj have a median target of 50.00, with a high estimate of 63.00 and a low estimate of 35.00. The median estimate represents a 10.84% increase from the last price of 45.11.
High39.7%63.00
Med10.8%50.00
Low-22.4%35.00

Dividends in EUR

In 2023, Orion Oyj reported a dividend of 1.62 EUR, which represents a 1.25% increase over last year. The 6 analysts covering the company expect dividends of 1.70 EUR for the upcoming fiscal year, an increase of 4.94%.
Div growth (TTM)1.25%
More ▼

Earnings history & estimates in EUR

On Oct 29, 2024, Orion Oyj reported 3rd quarter 2024 earnings of 1.14 per share. This result exceeded the 1.07 consensus of the 4 analysts covering the company and exceeded last year's 3rd quarter results by 0.70.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+51.90%
Orion Oyj reported annual 2023 earnings of 1.54 per share on Feb 13, 2024.
Average growth rate+9.96%
More ▼

Revenue history & estimates in EUR

Orion Oyj had 3rd quarter 2024 revenues of 471.30m. This bettered the 460.55m consensus of the 4 analysts covering the company. This was 69.59% above the prior year's 3rd quarter results.
Average growth rate+13.18%
Orion Oyj had revenues for the full year 2023 of 1.19bn. This was 11.26% below the prior year's results.
Average growth rate+4.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.